I seem to recall a story early on (like 2yrs ago) during this entire fluster cuck that the LNPs in particular were made by a CHINESE pharmaceutical company. There was some question back then that “there were quality issues with these LNPs.”
If I recall, the researcher was concerned with how easily the LNPs migrated and entered various cells and if they contained contaminants, real damage could be done.
It’s looking like EVRYTHING associated with China is crap.
Then again, I may be totally wrong on what I just recalled.
https://www.bristows.com/news/spotlight-on-mrna-ip-landscape/
From the article:
Early work on LNPs was carried out by Canadian biotech Arbutus Biopharma Corporation in collaboration with the University of British Columbia[8]. Several companies have since taken licences of LNP patents owned by Arbutus. In 2018, Arbutus spun out rights to its LNP technology (excluding rights to hepatitis B) into a company called Genevant Sciences GmBH as part of a joint venture with Roivant Sciences Ltd[9]. The Arbutus patents have also been the subject of some litigation (see below).